Indian startup develops drug for key orphan diseases, partners US firm
Oraxion Therapeutics, a spin-off from Aten Porus Lifesciences has entered into an agreement with a US-based biopharmaceutical company to license its lead asset ORX-301 for the treatment of Niemann-Pick Type C disorder and Focal Segmental Glomerulosclerosis